MRM
MEDIROM Healthcare Technologies Inc. (MRM) Economic Moat Analysis (2026)
Overall Score
Scale Market Position
MRM remains a sub-$1B market-cap business with limited scale, which constrains pricing power and competitive durability.
Revenue per share is high relative to the share price, but the business still lacks evidence of a defensible moat from the current data.
Profitability Returns
TTM margins are negative across EBIT, operating profit, pretax, and net income, indicating the core business is still unprofitable.
Returns are deeply negative, with ROA at -14.6%, ROIC at -19.3%, and ROE at -68.4%, showing no sign of economic moat-driven excess returns.
Balance Sheet Cash Generation
Liquidity is acceptable with a current ratio of 1.75, but cash ratio is only 0.01 and leverage remains elevated with debt-to-equity at 1.75.
Cash generation is weak, with negative operating cash flow and free cash flow, and a very long cash conversion cycle of 313 days.
Moat Evidence Resilience
Gross margin of 25.3% is not enough to offset the lack of operating leverage and persistent losses.
The business shows no clear evidence of switching costs, network effects, or durable cost advantage in the current financial profile.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on MEDIROM Healthcare Technologies Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

